Russian prostate cancer market expected to grow 6% annually from 2011 to 2016

The total number of diagnosed incident cases of prostate cancer in Russia will increase at five percent annually from 2011 to 2016, driven mostly by an aging population and the rising number of disease diagnoses, according to Prostate Cancer in Russia, a new report form health care advisory firm Decision Resources, which notes that the expanding patient population will largely contribute to the growth of the Russia’s prostate cancer drug market, which is forecasted to grow 6% annually over the next 10 years.